Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Treasury Shares (2021 - 2025)

Cytek Biosciences filings provide 5 years of Treasury Shares readings, the most recent being $5.1 million for Q2 2025.

  • On a quarterly basis, Treasury Shares rose 1057.97% to $5.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $5.1 million, a 1057.97% increase, with the full-year FY2023 number at $5.3 million, up 355.98% from a year prior.
  • Treasury Shares hit $5.1 million in Q2 2025 for Cytek Biosciences, down from $9.3 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $9.3 million in Q3 2024 to a low of $104876.0 in Q4 2021.
  • Median Treasury Shares over the past 5 years was $1.2 million (2022), compared with a mean of $2.9 million.
  • Biggest five-year swings in Treasury Shares: tumbled 85.63% in 2024 and later skyrocketed 1057.97% in 2025.
  • Cytek Biosciences' Treasury Shares stood at $104876.0 in 2021, then skyrocketed by 1015.13% to $1.2 million in 2022, then soared by 355.98% to $5.3 million in 2023, then soared by 73.5% to $9.3 million in 2024, then plummeted by 44.39% to $5.1 million in 2025.
  • The last three reported values for Treasury Shares were $5.1 million (Q2 2025), $9.3 million (Q3 2024), and $444319.0 (Q2 2024) per Business Quant data.